Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 37, 2007 - Issue 1
191
Views
33
CrossRef citations to date
0
Altmetric
Research Article

CYP2C76-mediated species difference in drug metabolism: A comparison of pitavastatin metabolism between monkeys and humans

, , , , &
Pages 30-43 | Received 30 Mar 2006, Accepted 07 Jul 2006, Published online: 22 Sep 2008

References

  • Aoki T, Yoshinaka Y, Yamazaki H, Suzuki H, Tamaki T, Sato F, Kitahara M, Saito Y. Triglyceride-lowering effect of pitavastatin in a rat model of postprandial lipemia. European Journal of Pharmacology 2002; 444: 107–113
  • Bogaards JJP, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, Bladeren PJ, Walther B. Determining the best animal model for human cytochrome P450 activities: A comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 2000; 12: 1131–1152
  • Daigo S, Takahashi Y, Fujieda M, Ariyoshi N, Yamazaki H, Koizumi W, Tanabe S, Saigenji K, Nagayama S, Ikeda K, Nishioka Y, Kamataki T. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 2002; 12: 299–306
  • Fujino H, Kojima J, Yamada Y, Kanda H, Kimata H. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4): Interspecies variation in laboratory animals and humans. Xenobiotic Metabolism and Disposition 1999a; 14: 79–91
  • Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T. Metabolic properties of the acid form and lactone form of HMG-CoA reductase inhibitors. Xenobiotica 2004b; 34: 961–971
  • Fujino H, Saito T, Tsunenari Y, Kojima J. Effect of gemfibrozil on the metabolism of pitavastatin – Determining the best animal model for human CYP and UGT activities. Drug metabolism and Drug Interactions 2004a; 20: 25–42
  • Fujino H, Yamada I, Hirano M, Yoneda M. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and human. Xenobiotic Metabolism and Disposition 1999b; 14: 415–424
  • Fujino H, Yamada I, Shimada S, Yoneda M, Kojima J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: Human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica 2003; 33: 27–41
  • Fujino H, Yamada I, Shimada S, Yoneda M. Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin-layer chromatography radioactivity assay. Journal of Chromatography 2001; 757: 143–150
  • Hichiya H, Kuramoto S, Yamamoto S, Shinoda S, Hanioka N, Narimatsu S, Asaoka K, Miyata A, Iwata S, Nomoto M, Satoh T, et al. Cloning and functional expression of a novel marmoset cytochrome P450 2D enzyme, CYP2D30: Comparison with the known marmoset CYP2D19. Biochemical Pharmacology 2004; 68: 165–175
  • Iwata H, Fujita K, Kushida H, Suzuki A, Konno Y, Nakamura K, Fujino A, Kamataki T. High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochemical Pharmacology 1998; 55: 1315–1325
  • Jacqz E, Billante C, Moysan F, Mathieu H. The non-human primate: A possible model for human genetically determined polymorphisms in oxidative drug metabolism. Molecular Pharmacology 1988; 34: 215–217
  • Kimata H, Fujino H, Koide T, Yamada Y, Tsunenari Y, Yonemitsu M. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats. Xenobiotic Metabolism and Disposition 1998; 13: 484–498
  • Kojima J, Fujino H, Yosimura M, Morikawa H, Kimata H. Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography (B) 1999; 724: 173–180
  • Komori M, Kikuchi O, Sakuma T, Funaki J, Kitada M, Kamataki T. Molecular cloning of monkey liver cytochrome P-450 cDNAs: Similarity of the primary sequences to human cytochromes P-450. Biochimica et Biophysica Acta 1992; 1171: 141–146
  • Ludwig E, Wolfinger H, Ebner T. Assessment of microsomal tolbutamide hydroxylation by a simple thin-layer chromatography radioactivity assay. Journal of Chromatography 1998; 707: 347–350
  • Matsunaga T, Ohmori S, Ishida M, Sakamoto Y, Nakasa H, Kitada M. Molecular cloning of monkey CYP2C43 cDNA and expression in yeast. Drug Metabolism and Pharmacokinetics 2002; 17: 117–124
  • Mise M, Hashizume T, Matsumoto S, Terauchi Y, Fujii T. Identification of non-functional allelic variant of CYP1A2 in dogs. Pharmacogenetics 2004; 14: 769–773
  • Narimatsu S, Kobayashi N, Masubuchi Y, Horie T, Kakegawa T, Kobayashi H, Hardwick JP, Gonzalez FJ, Shimada N, Ohmori S, Kitada M, et al. Species difference in enantioselectivity for the oxidation of propranolol by cytochrome P450 2D enzymes. Chemico-Biological Interactions 2000; 15: 73–90
  • Nedelcheva V, Gut I. P450 in the rat and man: Methods of investigation, substrate specificities and relevance to cancer. Xenobiotica 1994; 24: 1151–1175
  • Norgren Jr RB. Creation of non-human primate neurogenetic disease models by gene targeting and nuclear transfer. Reproductive Biology and Endocrinology 2004; 2: 40
  • Ohi H, Toratani S, Komori M, Miura T, Kitada M, Kamataki T. Comparative study of cytochrome P-450 in liver microsomes. A form of monkey cytochrome P-450, P-450-MK1, immunochemically cross-reactive with antibodies to rat P-450-male. Biochemical Pharmacology 1989; 38: 361–365
  • Prueksaritanont T, Gorham LM, Hochman JH, Tran LO, Vyas KP. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metabolism and Disposition 1996; 24: 634–642
  • Sharer JE, Shipley LA, Vandenbranden MR, Binkley SN, Wrighton SA. Comparisons of phase one and phase two in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metabolism and Disposition 1995; 23: 1231–1241
  • Stevens JC, Shipley LA, Cashman JR, Vandenbranden M, Wrighton SA. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities. Drug Metabolism and Disposition 1993; 21: 753–760
  • Suzuki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Atherosclerosis 1999; 146: 259–270
  • Tenmizu D, Endo Y, Noguchi K, Kamimura H. Identification of the novel canine CYP1A2 1117C > T SNP causing protein deletion. Xenobiotica 2004; 34: 835–846
  • Uno Y, Fujino H, Kito G, Kamataki T, Nagata R. CYP2C76, a novel CYP in cynomolgus monkey, is a major CYP2C in liver, metabolizing tolbutamide and testosterone. Molecular Pharmacology 70 2006; 477–486
  • Weaver RJ, Dickins M, Burke MD. A comparison of basal and induced hepatic microsomal cytochrome P450 monooxygenase activities in the cynomolgus monkey (Macaca fascicularis) and man. Xenobiotica 1999; 29: 467–482
  • Weaver RJ, Thompson S, Smith G, Dickins M, Elcombe CR, Mayer RT, Burke MD. A comparative study of constitutive and induced alkoxyresorufin O-dealkylation and individual cytochrome P450 forms in cynomolgus monkey (Macaca fascicularis), human, mouse, rat and hamster liver microsomes. Biochemical Pharmacology 1994; 47: 763–773
  • Yamada I, Fujino H, Shimada S, Kojima J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: Similarities and difference in the metabolism of pitavastatin in monkeys and humans. Xenobiotica 2003; 33: 789–803

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.